氨溴索预防新生儿呼吸窘迫综合征的系统评价  

Efficacy and Safety of Ambroxol in the Prevention of Neonatal Respiratory Distress Syndrom: A Systematic Review

作　　者：程艳霞[1] 邹敏[1] 任林[1] 唐尧[1] 

机构地区：[1]四川大学华西医院药剂科,成都市610041

出　　处：《中国药房》2011年第44期4201-4203,共3页China Pharmacy

摘　　要：目的:系统评价氨溴索预防新生儿呼吸窘迫综合征(NRDS)的疗效和安全性。方法:计算机检索PubMed、EMBase、ISI、中国生物医学文献数据库(CBM)、中国期刊全文数据库(CNKI)、中文科技期刊全文数据库(VIP)、万方数字化期刊全文数据库和Cochrane图书馆,纳入氨溴索对比常规/安慰剂预防NRDS的随机对照试验(RCT),对纳入的RCT进行方法学质量评价和Meta分析。结果:共纳入13项RCT,合计1377例患儿。2组NRDS发生率[RR=0.44,95%CI(0.32,0.61),P<0.00001]、发生NRDS后死亡率[RR=0.40,95%CI(0.17,0.94),P=0.03]以及并发症发生率差异均有统计学意义[RR=0.10,95%CI(0.05,0.19),P<0.00001]。2组不良反应发生率比较差异无统计学意义。结论:氨溴索能降低NRDS发生率、减少发生NRDS后的死亡率和并发症。OBJECTIVE： To evaluate efficacy and safety of ambroxol in the prevention of neonatal respiratory distress syndrome （NRDS）. METHODS： Random controlled trails （RCT） of ambroxol vs. placebo for NRDS were retrieved from Cochrane library, PubMed, EMBase, ISI, CBMdisc, CNKI, VIP, Wangfang database. Quality evaluation and Meta-analysis of included studies were conducted. RESULTS： 13 RCTs involving 1 377 patients of ambroxol vs. placebo in the prevention of NRDS were included. The incidence of NRDS in 2 groups had statistical significance [RR=0.44, 95%CI（0.32,0.61）, P〈0.000 01]; the mortality after NRDS in 2 groups had statistical significance [RR=0.40,95%CI（0.17,0.94）,P=0.03]; the incidence of complication had statistical significance [RR=0.10,95%CI（0.05,0.19）, P〈0.000 01]. There was no statistical significance in the difference of ADR. CONCLUSION： According to the evidence currently, ambroxol in the prevention of NRDS could decrease the incidence of NRDS and the mortality after NRDS, reduce the incidence of complication.

关 键 词：氨溴索 新生儿呼吸窘迫综合征 有效性 安全性 META分析 

分 类 号：R722.19[医药卫生—儿科]